Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BASECURE THERAPEUTICS LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. The portfolio also involves 2 distinct art units. POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner and is responsible for 1 pending office action. The number of pending office actions is equal to the number of distinct examiners, which means each case is reviewed by a different person.
The 2 distinct art units indicate that the Biotechnology & Pharmaceuticals filings are not concentrated in a single group. Practitioners must navigate the different examination styles of the 2 distinct examiners. POLIAKOVA-GEORGAN, EKATERINA handles 1 of the 2 pending office actions. The 2 distinct art units may have different technical standards for the Biotechnology & Pharmaceuticals field. This distribution requires a strategy that accounts for different perspectives within the patent office.
The Biotechnology & Pharmaceuticals technology area is the focus of these 2 pending office actions. Each of the 2 distinct examiners is associated with one of the 2 distinct art units. POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner despite only having 1 pending office action. This structure requires the company to monitor separate timelines and procedural requirements for each application. The 2 distinct examiners will provide individual feedback on the claims.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | VANHORN, ABIGAIL LOUISE | 28d |
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 76d |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103 | Final Rejection | 76d | Pending | Jun 20, 2025 |
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | VANHORN, ABIGAIL LOUISE | 1636 | §103Other | Non-Final OA | 28d | Pending | Jun 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBASECURE THERAPEUTICS LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ekaterina Poliakova-Georgan has the most, with 1 of BASECURE THERAPEUTICS LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
